Woman denied cancer drug on NHS which could extend her life because of where she lives

22 January 2020 - Ann, 64, can't get the drug she needs to survive because it's not available on the NHS ...

Read more →

NHS patients denied new lung cancer drug after another NICE deadlock

22 January 2020 - Certain untreated lung cancer patients on England’s NHS will have to make do with older drugs ...

Read more →

EU group calls for 'targeted actions' to mitigate impact of Brexit

22 January 2020 - Committee wants to ensure safe supply of drugs and medical devices. ...

Read more →

NICE rejects Janssen’s Stelara on cost efficiency grounds

22 January 2020 - NICE has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ...

Read more →

Achieving cost savings with biosimilars will require new strategies, authors say

20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...

Read more →

After 20 years of using economic evaluation, should NICE be considered a methods innovator?

13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...

Read more →

Closing the cycle of innovation in health care in Europe

17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...

Read more →

Pricing of pharmaceuticals is becoming a major challenge for health systems

13 January 2020 - Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable. ...

Read more →

Defining the concept of fair pricing for medicines

13 January 2020 - Suerie Moon and colleagues consider what makes a fair price for both buyers and sellers. ...

Read more →

Use of patient preference studies in HTA decision making: a NICE perspective

16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...

Read more →

NICE encourages further data collection on ‘game changing’ histology independent cancer drugs

17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...

Read more →

NICE ‘OK’ for Lynparza

16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...

Read more →

Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund

15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...

Read more →

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance. ...

Read more →

NICE rejects Keytruda, asks for more information

15 January 2020 - NICE has published a new draft guidance not recommending MSD’s cancer blockbuster Keytruda (pembrolizumab) for untreated ...

Read more →